Kelly Martin, chief executive of Elan, said the Irish drugs group would focus on increasing sales of its multiple sclerosis drug Tysabri, following the sale of a stake in the business to Johnson & Johnson last month.

Tysabri, which accounts for two-thirds of group turnover, saw sales jump 19 per cent in the third quarter, with more than 45,000 patients in Europe and the US taking the drug.